A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-08

Study Completion Date

2018-02-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bilthoven Biologicals has developed a new bivalent oral polio vaccine (bOPV) containing World Health Organization (WHO) approved Sabin strains of poliovirus type 1 and type 3. This study will assess non-inferiority of bOPV manufactured by BBio to that of licensed bOPV. This study will also assess lot-to-lot consistency among three lots of BBio bOPV.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine

NCT02291263

Poliomyelitis

COMPLETED PHASE3

Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV

NCT06114810

Polio

UNKNOWN PHASE4

Immunogenicity of Inactivated and Live Polio Vaccines

NCT01813604

Poliomyelitis

COMPLETED PHASE3

Immunogenicity nOPV2 With and Without bOPV

NCT04579510

Poliomyelitis

COMPLETED PHASE2

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

NCT05644184

Poliomyelitis

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bilthoven Biologicals has developed a new bivalent OPV containing WHO approved Sabin strains of poliovirus type 1 and type 3. This phase III study will be conducted in two parts:

Part 1 - 40 children of 60 to 83 months of age will be given single dose of BBio bOPV or licensed bOPV in 1:1 ratio. Primary objective is to assess safety of BBio bOPV.

Part 2 - A total of 1080 infants of 42 to 56 days of age will be randomized to receive three doses of either BBio bOPV from one of the three lots or a licensed bOPV in 1:1:1:1 ratio as primary immunization series at 6, 10 and 14 weeks of age.

Primary objective of this study is to assess non-inferiority of bOPV manufactured by BBio to that of licensed bOPV in terms of seroconversion. This study also will assess lot-to-lot consistency among three lots of BBio bOPV.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune Response to Oral Polio Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1 Study - BBio bOPV

Group Type EXPERIMENTAL

Part 1 study - BBio bOPV

Intervention Type BIOLOGICAL

A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.

Part 1 Study - Licensed bOPV

Group Type ACTIVE_COMPARATOR

Part 1 study - Licensed bOPV

Intervention Type BIOLOGICAL

A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.

Part 2 Study - BBio bOPV Lot 1

Group Type EXPERIMENTAL

Part 2 study - BBio bOPV Lot 1

Intervention Type BIOLOGICAL

Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Part 2 Study - BBio bOPV Lot 2

Group Type EXPERIMENTAL

Part 2 study - BBio bOPV Lot 2

Intervention Type BIOLOGICAL

Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Part 2 Study - BBio bOPV Lot 3

Group Type EXPERIMENTAL

Part 2 study - BBio bOPV Lot 3

Intervention Type BIOLOGICAL

Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Part 2 Study - Licensed bOPV

Group Type ACTIVE_COMPARATOR

Part 2 study - Licensed bOPV

Intervention Type BIOLOGICAL

Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Part 1 study - BBio bOPV

A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.

Intervention Type BIOLOGICAL

Part 2 study - BBio bOPV Lot 1

Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention Type BIOLOGICAL

Part 2 study - BBio bOPV Lot 2

Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention Type BIOLOGICAL

Part 2 study - BBio bOPV Lot 3

Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention Type BIOLOGICAL

Part 2 study - Licensed bOPV

Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.

Intervention Type BIOLOGICAL

Part 1 study - Licensed bOPV

A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Normal healthy children of both sexes of age 5 to 6 years (60-83 months) at the time of vaccination and who have received at least 3 doses of trivalent oral polio vaccine (tOPV) based upon documentation (Study Part 1).
2. Normal healthy infants of both sexes of age 6-8 weeks (42-56 days) at the time of the first vaccination and have not received oral polio vaccine (OPV) previously based upon documentation (Study Part 2).
3. Parents/legal guardians of participants willing to give written informed consent and willing to comply with study protocol.
4. Free of obvious health problems as established by medical history and screening evaluation including clinical examination.
5. Resident of study area.

Exclusion Criteria

1. Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination or planned participation in another clinical trial during the present trial period.
2. A diagnosis or suspicion of congenital or acquired immunodeficiency disorder, malignancy, receiving immunosuppressive therapy such as systemic corticosteroids therapy for a period of ≥ 1 week either in the participant or in an immediate family member.
3. A diagnosis or suspicion of bleeding disorder that would contraindicate collection of blood by venipuncture.
4. Acute or persistent diarrhea (defined as diarrhea that lasts 14 days or longer), infection or illness at the time of enrollment (6-8 weeks of age) that would require participant's admission to a hospital or would contraindicate provision of OPV.
5. Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit.
6. Infants from multiple births (i.e. twins).
7. History of allergy or systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the study vaccines or a vaccine containing the same substances.
8. Chronic illness at a stage that could interfere with trial conduct or completion.
9. Planned administration/ administration of a vaccine not foreseen by the study protocol during the study period with the exception of routine Expanded Program on Immunization (EPI) program vaccines including pneumococcal vaccine, and rotavirus vaccine (Polio vaccines are not allowed during the study period).
10. Blood or blood-derived products received in the past.
11. Any vaccination one week preceding the trial vaccination.
12. Presence of significant malnutrition (\< -3 standard deviation \[SD\] weight for length) or acute or chronic, clinically significant pulmonary, endocrine, autoimmune, cardiovascular, metabolic, hepatic or renal functional abnormality, as determined by medical history, and physical examination, which in the opinion of the investigator, might interfere with the study objectives
13. History of any neurological disorder or history of seizure (febrile or afebrile), or encephalopathy, encephalitis, hypotonic-hyporesponsive episode.
14. Febrile illness or acute illness on the day of inclusion is temporary exclusion criterion.
15. Participant with any other condition, which, in the opinion of the investigator would jeopardize the safety or rights of the participant participating in the study or making it unlikely the participant, could complete the protocol.

Minimum Eligible Age

42 Days

Maximum Eligible Age

83 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes